Life Molecular Imaging started recruitment for longitudinal Phase 2 Study with the Tau tracer PI-2620 17. September 201913. October 2019lifemolecular Click to read more: The new study will thoroughly assess the accumulation and spread of Tau depositions in patients with Alzheimer’s disease and in subjects with mild cognitive impairment as visualized by PI-2620 brain uptake Teilen mit:TwitterFacebookLike this:Like Loading...